PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts maintain a “Hold” consensus on PROCEPT BioRobotics, with nine hold, three buy, one strong-buy and two sell ratings. The average 12-month price target is $25.09, compared with the stock’s reported price of $19.30.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year and above expectations, but its adjusted loss of $0.47 per share narrowly missed estimates. Analysts expect a full-year loss of approximately $1.67 per share.
• Investor uncertainty has increased amid securities class-action allegations involving weaker handpiece sales, excess customer inventory and discounting practices; the reported lead-plaintiff deadline is September 22, 2026. Institutional investors own 89.46% of the company, while CEO Larry Wood recently purchased roughly $498,000 of shares.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) has been given a consensus recommendation of "Hold" by the fifteen analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $25.0909.

PRCT has been the subject of several research analyst reports. Wells Fargo & Company cut shares of PROCEPT BioRobotics from an "overweight" rating to an "equal weight" rating and set a $19.00 target price for the company. in a research report on Wednesday, August 5th. Evercore set a $23.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Citigroup lowered shares of PROCEPT BioRobotics to a "hold" rating in a report on Thursday, July 2nd. Piper Sandler cut their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th.

Insiders Place Their Bets

In other news, CEO Larry Wood purchased 23,900 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 1,043 shares of company stock valued at $21,851 over the last 90 days. 4.00% of the stock is owned by corporate insiders.

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds have recently modified their holdings of the business. Johnson & Johnson bought a new position in shares of PROCEPT BioRobotics in the 2nd quarter worth about $8,082,263. Quantinno Capital Management LP bought a new stake in PROCEPT BioRobotics during the first quarter worth about $1,693,000. Bank of America Corp DE grew its holdings in PROCEPT BioRobotics by 46.3% in the first quarter. Bank of America Corp DE now owns 630,689 shares of the company's stock worth $15,774,000 after purchasing an additional 199,484 shares during the period. Rhenman & Partners Asset Management AB grew its holdings in PROCEPT BioRobotics by 56.7% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 611,000 shares of the company's stock worth $19,222,000 after purchasing an additional 221,000 shares during the period. Finally, Corient Private Wealth LP bought a new position in shares of PROCEPT BioRobotics during the second quarter valued at approximately $2,448,000. Institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Trading Down 0.9%

PRCT opened at $19.30 on Friday. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $39.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The business has a 50 day simple moving average of $20.16 and a two-hundred day simple moving average of $23.25. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -9.95 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The business had revenue of $94.50 million for the quarter, compared to analysts' expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. PROCEPT BioRobotics's quarterly revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted ($0.35) earnings per share. Analysts predict that PROCEPT BioRobotics will post -1.67 EPS for the current year.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: A federal securities class action has been filed on behalf of investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026 to seek appointment as lead plaintiff. Kaplan Fox class action notice
• Negative Sentiment: The allegations reportedly center on weaker-than-expected unit handpiece sales, excess customer inventory and repeated late-quarter bulk discounts. The complaint also challenges company explanations that revenue volatility was caused by temporary saline shortages. Hagens Berman investor alert
• Negative Sentiment: Multiple law firms, including Robbins Geller, Bragar Eagel & Squire, Pomerantz, SBS Law and Bernstein Liebhard, issued substantially similar investor alerts. The volume of announcements may amplify uncertainty around PROCEPT’s sales practices, demand outlook and potential litigation costs. Robbins Geller investor deadline notice

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for urologic care. The company's primary focus is the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

Its flagship product is the AQUABEAM Robotic System, which uses image guidance, robotics, and high-velocity waterjet technology to remove targeted prostate tissue without the use of a traditional cutting instrument.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.